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15 Frequency of mutations of the cystic ﬁbrosis transmembrane
regulator (CFTR) gene in a cohort of consecutive patients
candidate for assisted reproductive techniques
M. Rongioletti1, F. Papa1, M.B. Majolini1, C. Vaccarella1, I. Simonelli2,
A. Luciano1, P. Pasqualetti2, G.M. Liumbruno1. 1“San Giovanni Calibita”
Fatebenefratelli Hospital, Clinical Pathology Laboratory, Molecular Biology Unit,
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Objectives: An association between cystic ﬁbrosis transmembrane regulator
(CFTR) gene mutations and infertility may occur. This study investigated the
frequency of mutations in the CFTR gene, in a group of consecutive patients
candidate for assisted reproductive techniques with the aim of identify subjects
carriers of the most severe ones.
Methods: We screened 11208 healthy subjects (5943 females and 5265 males)
for 56 CFTR gene mutations and IVS8-poliT polymorphism utilizing the CFTR
INNO-LiPA Ampliﬁcation kit including both general and Italian regional strips.
The frequency of mutations were separately calculated and the Chi-square test was
used for comparisons.
Conclusions: CFTR mutations were detected in 6.2% of the patients, a percentage
similar to that reported in the general population. The most common mutation was
DF508/N observed in 0.9% of patients. No difference in the gender distribution was
evidenced. In the large group of patients analyzed 87.7% were wt, 11.8% carrier
of one mutation, and interestingly 0.5% compound heterozygous.
Our data support the relevance of an accurate determination of mutations in the
CFTR gene in order to inform the couple of their carrier risk and the possibility
on having affected child. Moreover, our ﬁndings highlight the potential of genetic
screening as a tool to identify possible compound heterozygous subjects without
CF-like symptoms.
Acknowledgements: The authors wish to thanks the directors and their staff of the
following assisted reproduction centres, for their greatly appreciated collaboration:
Clinica Villa Salaria, Rome; G.EN.E.R.A, Clinica Valle Giulia, Rome; European
Hospital, Rome; Clinica Villa Margherita, Rome; One Day Medical Centre, Rome;
Nike Centre, Rome; CERMER, Clinica Villa Mafalda, Rome; S. Anna Hospital,
Rome; Sandro Pertini Hospital, Rome; San Filippo Neri Hospital, Rome; Santa
Maria Goretti Hospital, Latina.
16 Newborn screening for cystic ﬁbrosis in Switzerland −
Consequences after analysis of 4 months pilot study
T. Torresani1, R. Fingerhut1, S. Gallati2, M.H. Schoeni3, M. Baumgartner4,
J. Barben5. 1University Children’s Hospital, Swiss Newborn Screening Laboratory,
Zu¨rich, Switzerland; 2University Children’s Hospital, Division of Human Genetics,
Berne, Switzerland; 3University Children’s Hospital, Outpatient Department,
Berne, Switzerland; 4University Children’s Hospital, Division of Metabolism and
Swiss Newborn Screening, Zu¨rich, Switzerland; 5Children’s Hospital, Dept. of
Pulmonology, St. Gallen, Switzerland
Background: Newborn screening for cystic ﬁbrosis (CF), based on immunoreactive
trypsinogen (IRT) and 7 most common CFTR mutations, was introduced in
Switzerland on January 1st, 2011. The suggested IRT value for the 99th percentile
from the literature was 60 ng/ml. In a test run in December 2010, the corresponding
IRT value for the 99th percentile turned out to be lower (45 ng/ml). One aim of this
pilot study was to ﬁnd out if this cut-off is too low and resulting in unnecessary
2nd IRT measurements if no CFTR mutations were found.
Methods: We evaluated the IRT cut-off, recall rate, the number of children referred
to a CF centre, and compared it to IRT values of the conﬁrmed diagnosis. All
children referred to a CF centre had an additional IRT measurement when sweat
testing was performed.
Results: In the ﬁrst 4 months, 27,297 IRT tests were performed, 0.92% of them
(251/27,297) were above 45 ng/ml, and DNA screening was performed. In 211
children, a 2nd IRT measurement was necessary (recall rate 0.77%). 40 children
were referred to a CF centre (referral rate 15.9%) and the positive predictive value
was 20% (8/40). No child with CF had an IRT value <50 ng/ml. All 15 children
with initial IRT between 45 and 60 ng/ml and no CFTR mutations had a normal 2nd
IRT test. After changing the IRT cut-off, the recall rate decreased by 45%: In the
further 8 months, only 228 children needed an 2nd IRT test and 45 were referred
to a CF centre for sweat testing, and only 4 out of them had twice an elevated IRT
value but no CFTR mutation.
Conclusions: The change of the IRT cut-off from 45 to 50 ng/ml (99.5th percentile)
resulted in less recalls without losing diagnostic accuracy.
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Introduction: Since June 2010, the Public Health Ministry in Uruguay decreed
mandatory the newborn screening for Cystic Fibrosis (CF). Our algorithm is to
perform the immuno-reactive trypsin (IRT) in dried blood spot. If this IRT value is
higher than the cut off we request another sample which must be collected before
30 days of baby’s life. However, the second sample does not come on time to
perform the IRT so we started a pilot program with a second marker: pancreatitis-
associated protein (PAP). PAP is done to all ﬁrst sample with IRT elevated as well
as to every second sample.
Objective: To present the results of our newborn screening of CF in the pilot
program.
Materials and Methods: The samples used were dried blood spots on Whatman
S&S 903 ﬁlter paper, the ﬁrst one is taken with 40 hours of life. The methods
used are IRT Quantase enzyme immunoassay BIORAD and Mucopap enzyme
immunoassay DYNABIO optimized.
Results: From April to November 2011 we processed 32650 samples. 289 samples
were high for IRT, to this samples we performed PAP and 57 of them were positive.
These patients were called to conﬁrm the CF by sweat test and molecular analysis.
7 patients were conﬁrmed by both methods. Positive predicted value (PPV) was
2.4% for IRT-IRT algorithm and increased to 12.3% with IRT-PAP algorithm.
Conclusions: With IRT-PAP algorithm we have a speciﬁc and sensitive program
for the detection of CF. One of the advantages of this marker is that is useful
independently of the time the sample is collected, which give us more time to
deﬁne the diagnosis of the patients. With this algorithm we believe we can solve
problem related to the delay of the second sample.
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Objectives: Newborn screening (NBS) for cystic ﬁbrosis (CF) has been imple-
mented in the form of nationwide Immunoreactive trypsinogen (IRT) / DNA/IRT
scheme in the Czech Republic since autumn 2009. Total number of 84 485 children
were born and examined for CF in the Moravian part of the Czech Republic in two
years period. The aim was to evaluate incidence of CF and frequency of pathologic
alelas in CFTR gene.
Methods: Dry blood spot was checked for IRT. Levels above 65 ng/ml were sent
to molecular analyses, where they were screened for 50 mutations. Children with
only one mutation were invited for sweat test.
Results: Elevated IRT was detected in 953 cases out of the total 84 585. Thirteen
CF children were diagnosed. All of them were symptomatic already in 6 weeks.
After adequate therapy, all of them are in very good status. Four children were
heterozygous for two mutations but with sweat test under 30mmol/l and healthy.
We detected combination of F508del/R117H twice, and both F508del/D1152 and
N1303K/D1152H once. Another 78 children with one mutation were checked, all
were healthy.
During the last two years we diagnosed one CF in 6 020 newborns. There were
only 14 types of pathologic alelas. F508del was the most frequent mutation in 58%
followed by D1152H and R117H.
One baby passed NBS undetected with IRT 61 ng/ml respective 40 ng/ml and was
diagnosed as CF homozygous F508del because of clinical symptoms later at the
age of 8 weeks.
Conclusions: We can conﬁrm that NBS is a valuable method; all CF children
diagnosed at early age are doing well. In symptomatic babies with negative NBS it
is necessary to perform sweat test as well. Failure of NBS is possible.
